Compound News and Research

RSS

New dye more effective in detecting, measuring cardiolipin in cell membranes

A team that includes Dartmouth College researchers has discovered a new way to detect cardiolipin, a key indicator of heart diseases and some genetic disorders.

16 Jan 2014

New discovery has potential to transform heart attack treatments

An Australian discovery has the potential to transform the treatment of a heart attack, after a new approach boosted heart function and reduced heart scarring in preclinical studies.

16 Jan 2014

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

15 Jan 2014

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.

10 Jan 2014

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill.

10 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Slower decline for patients with PARKIN-associated PD

Cognitive and motor decline may be slower in patients with early-onset Parkinson’s disease if they have PARKIN mutations, suggests an analysis of the Consortium on Risk for Early-Onset PD study.

8 Jan 2014

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.

8 Jan 2014

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

BioDefense Therapeutics—a Joint Product Management office within the U.S. Department of Defense—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through a contract with Boston-based MediVector, Inc.

7 Jan 2014

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Fungi have played a large role in the development of many important drugs that are in wide use today. The most well-known of these are the penicillins.

7 Jan 2014

Synthetic cannabinoid molecule created for osteoarthritis

Chemical compounds synthesised in the laboratory, similar to those found in cannabis, could be developed as potential drugs to reduce the pain of osteoarthritis.

7 Jan 2014

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

7 Jan 2014

Researchers discover novel compounds that are hundreds of times more mutagenic

Researchers at Oregon State University have discovered novel compounds produced by certain types of chemical reactions - such as those found in vehicle exhaust or grilling meat - that are hundreds of times more mutagenic than their parent compounds which are known carcinogens.

6 Jan 2014

Autism Speaks grants $2.7M to develop potential treatments for ASD, increase access to high-quality early intervention

Autism Speaks, the world's leading autism science and advocacy organization, today announced the award of nearly $2.7 million for the funding of 13 new research projects over the next three years.

6 Jan 2014

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.

6 Jan 2014

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

A compound derived from a traditional Chinese herbal medicine has been found effective at alleviating pain, pointing the way to a new nonaddictive analgesic for acute inflammatory and nerve pain, according to UC Irvine pharmacology researchers.

3 Jan 2014

Combination of NGF microspheres and chitosan conduits exhibit better effects in repairing facial nerve injury

The chitosan molecule can promote nerve cell adherence and growth along the surface of the material. It can enhance the adherence and influx of Schwann cells, thus encouraging the growth of axons.

28 Dec 2013

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout.

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Compound News and Research

New dye more effective in detecting, measuring cardiolipin in cell membranes

New discovery has potential to transform heart attack treatments

BMH-21 chemical compound has ability to shut down a common cancer process

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Researchers deploy potential new weapon against HIV

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Slower decline for patients with PARKIN-associated PD

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Synthetic cannabinoid molecule created for osteoarthritis

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Researchers discover novel compounds that are hundreds of times more mutagenic

Autism Speaks grants $2.7M to develop potential treatments for ASD, increase access to high-quality early intervention

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

Combination of NGF microspheres and chitosan conduits exhibit better effects in repairing facial nerve injury

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News